Multivalent OspA Fusion Vaccine for Broad Lyme Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no effective vaccine available to prevent Lyme disease, and existing OspA-based vaccines face challenges such as potential autoimmune reactions and the need for high and sustained antibody titers due to their mechanism of action outside the body, necessitating frequent booster shots.
Innovation Solution
A multivalent Lyme borreliosis vaccine comprising lipidated mutant OspA fragment fusion proteins, targeting the C-terminal parts of six common OspA serotypes, is administered in specific doses and schedules to induce high antibody titers, preventing Borrelia transmission by neutralizing spirochetes in the tick gut.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If OspA-based vaccines are administered to prevent Lyme disease, then antibody titers are induced, but frequent booster shots are required to maintain protection
Solution Approach 1:
The patent combines multiple OspA serotypes (ST1, ST2, ST4, ST5, ST6) into a single multivalent vaccine formulation. This merging of different serotypes into one vaccine addresses the contradiction by providing broad, sustained protection against multiple Borrelia genospecies simultaneously, eliminating the need for frequent boosters while maintaining reliable protective efficacy.
Solution Approach 2:
The vaccine achieves multi-functionality by incorporating fusion proteins that target six different OspA serotypes. This universal approach provides protection against diverse Borrelia strains in a single administration, resolving the contradiction between maintaining reliable protection and avoiding frequent boosters through sustained, broad-spectrum immunity.
2Reliability
If OspA-based vaccines are used, then protection against Lyme disease is achieved, but autoimmune reactions may occur
Solution Approach 1:
The patent employs fusion proteins with specific local modifications, including N-terminal lipidation and C-terminal truncation, to target only the protective epitopes of OspA while excluding regions that may trigger autoimmune responses. This local quality modification maintains protective efficacy while reducing harmful autoimmune reactions.
Solution Approach 2:
The vaccine design converts potentially harmful full-length OspA proteins into beneficial truncated fusion proteins that retain protective immunogenicity while eliminating autoimmune-triggering regions. This transformation maintains protective efficacy while converting the harmful potential of OspA into a safe and effective vaccine.
3Ease of manufacture
If a single serotype vaccine is administered, then production is simplified, but protection is limited to specific Borrelia strains
Solution Approach 1:
The patent merges multiple serotype-specific OspA genes into a single multivalent vaccine formulation, achieving both simplified production (one vaccine product) and broad serotype coverage (six different serotypes). This resolving of the contradiction allows manufacturers to produce a single versatile vaccine that protects against diverse Borrelia strains.
Solution Approach 2:
The multivalent vaccine achieves universality by incorporating fusion proteins targeting six different OspA serotypes in one formulation. This multi-functional approach simultaneously simplifies manufacturing (single product) while maximizing adaptability and coverage against multiple Borrelia genospecies and serotypes.
Data Source
AI summary
The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipS1D1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.